Skip to content

Clinical study of siddha medicine Nandhi mezhugu in the treatment of Rheumatoid arthritis

Pre-clinical and clinical evaluation of safety and efficacy of a Siddha Herbo- Mineral formulation Nandhi Mezhugu in the treatment of Uthira Vatha Suronitham(Rheumatoid Arthritis) - SAESFNMIRA

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/05/013762
Enrollment
40
Registered
2018-05-08
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- UTHIRAVATHASURONITHAM(RHEUMATOID ARTHRITIS)

Interventions

Intervention1: NANDHI MEZHUGU(Internal): DOSAGE:500 mg twice a day with palm jaggery after food for 60 days with drug holiday Intervention2: NANDHI MEZHUGU: 500mg with palm jaggery BD oral route 60 da

Sponsors

AYOTHIDOSS PANDITHAR HOSPITAL
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Pain and swelling in smaller and major joints. 2.Symmetrical joint involvement. 3.More than 3 joints involved. 4.Fever. 5.Morning stiffness. 6.Serum positive Anti CCP

Exclusion criteria

Exclusion criteria: 1.Diabetes mellitus. 2.Hypo & Hyperthyroidism. 3.Hypertension. 4.Cardiac disease. 5.Renal disease. 6.Liver disorder. 7.Neurological disorders. 8.Pregnancy and Lactation. 9.Alcoholism. 10.Recent treatment with steroids.

Design outcomes

Primary

MeasureTime frame
Reduction of pain(assessed by universal pain assessment scale) of the joints,and improvement in the movement of the affected joints( Restricted movement assessment scale) and improvement in the quality of life(assessed by Modified health assessment Questionnaire)Timepoint: AFTER COMPLETION OF 60 DAYS TREATMENT.

Secondary

MeasureTime frame
1.Reduction of other clinical symptoms like low grade fever, anorexia etc. 2.Reduction in Anti-CCP and RA factor. 3.Reduction of ESR and CRP 4. other variables like age , gender,occupation, socioeconomic status,seasonal variation,duration of illness will be studied . Timepoint: After the treatment period of 60 Days

Countries

India

Contacts

Public ContactProf Dr G GANAPATHY

National Institute of Siddha,Chennai-47

drgganapathy@gmail.com9444182228

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026